The Ministerial Reliance Order: Eligible drugs
On this page
- About the IbR list of classes of drugs and foreign regulatory authorities
- Making changes to the IbR list
About the IbR list of classes of drugs and foreign regulatory authorities
The IbR list is called the "List of classes of drugs and foreign regulatory authorities for the purposes of reliance on decisions or documents". It can be changed at any time. It indicates the classes of drugs that are eligible for deeming. Foreign regulatory authorities (FRAs) are also listed for the applicable class of drugs.
The IbR list is separated into human drugs and veterinary drugs to make it easier to find the relevant information. It has parts, divisions and subdivisions based on the type of submission and deeming scenario.
Health Canada is taking a risk-based, phased approach to adding to the IbR list. The first version of the list was made available when the Order was published in Canada Gazette, Part II on July 15, 2026.
For classes of human drugs included on the IbR list, the following scenarios are available for phase 1:
- general deeming (including for pediatric use) and
- joint review
For classes of veterinary drugs included on the IbR list, there are general deeming and 120-day deeming scenarios as part of phase 1.
Visit the IbR lists:
- IbR list of classes of drugs and foreign regulatory authorities for reliance: Human drugs
- IbR list of classes of drugs and foreign regulatory authorities for reliance: Veterinary drugs
Making changes to the IbR list
Health Canada will maintain and update this list when required. Before updating a class of drugs or FRA to the IbR List, an assessment will be done to determine whether including the class of drugs on the List:
- is needed for health or safety reasons or is in the public interest and
- is unlikely to lead to unacceptable risks or uncertainties to health, safety or the environment
Our approach to making changes to the list is consistent with our policy on incorporation by reference. The process for making changes to the IbR list is outlined in the draft guidance.
Learn more: